Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Extracellular vesicle-mediated gene therapy targets BRAFV600E-mutant colorectal cancer by inhibiting the MEK1/2-ERK1/2 pathway

20 Feb 2025

Abstract excerpt

Patients with colorectal cancer (CRC) harboring BRAF mutation have a poor prognosis. The median survival time for patients with advanced BRAF V600E -mutant CRC is only approximately one year. Owing to the insensitivity to standard chemotherapy, there are still no effective and highly specific treatment strategies available in clinical practice for CRC patients with BRAF mutation. Therefore, targeting the BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Adhesion Molecules Research
Share to Extracellular vesicles in disease
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39979881
DOI: 10.1186/s12951-025-03205-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Extracellular vesicle-mediated gene therapy targets BRAFV600E-mutant colorectal cancer by inhibiting the MEK1/2-ERK1/2 pathwayPMID 39979881Read ↗

Tumor-Secreted Extracellular Vesicles Regulate T-Cell Costimulation and Can Be Manipulated To Induce Tumor-Specific T-Cell Responses.Semantic proximity Read ↗

Colorectal cancer-derived exosomes and modulation KRAS signaling.Semantic proximity Read ↗

Detection of KRAS Mutations Using Extracellular Vesicle DNA in Colorectal Cancer PatientsSemantic proximity Read ↗

Harnessing extracellular vesicles for efficient siRNA delivery <i>in vitro</i> and <i>in vivo</i>Semantic proximity Read ↗

BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells.Semantic proximity Read ↗

Allogeneic Tumor Cell-Derived Extracellular Vesicles Stimulate CD8 T Cell Response in Colorectal CancerSemantic proximity Read ↗

Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma.Semantic proximity Read ↗

Reovirus sensitizes microsatellite stable colorectal cancer to anti-PD-1 treatment via cross-talk in innate and adaptive immune systemsSemantic proximity Read ↗

CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor TherapySemantic proximity Read ↗

Extracellular vesicles in anti-tumor drug resistance: Mechanisms and therapeutic prospectsSemantic proximity Read ↗

Tumor-derived extracellular vesicles in the colorectal cancer immune environment and immunotherapySemantic proximity Read ↗

Isolation of extracellular vesicles improves the detection of mutant DNA from plasma of metastatic melanoma patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.